VEDOLIZUMAB IN THE MANAGEMENT OF INFLAMMATORY BOWEL DISEASES: A BRAZILIAN OBSERVATIONAL MULTICENTRIC STUDY.
Arq Gastroenterol
; 56(3): 312-317, 2019.
Article
em En
| MEDLINE
| ID: mdl-31633731
ABSTRACT
BACKGROUND:
There is scarce data regarding efficacy and safety of vedolizumab in inflammatory bowel diseases in Latin America.OBJECTIVE:
To describe the first observational real-world experience with vedolizumab in Latin American inflammatory bowel diseases patients.METHODS:
Retrospective observational multicentric study of patients with Crohn's disease (CD) and ulcerative colitis (UC) who used vedolizumab at any phase of their treatment. Clinical remission and response (according to Harvey-Bradshaw index for CD and Mayo score for UC), mucosal healing, need for surgery and adverse events were evaluated.RESULTS:
A total of 90 patients were included (52 with CD and 38 with UC), the majority with previous exposure to anti-TNF agents (88.46% in CD and 76.31% in UC). In CD (as observed analysis) remission rates at weeks 12, 26 and 52 were 42.89% (21/49), 61.9% (26/42) and 46.15% (12/26), respectively. In UC, remission rates at weeks 12, 26 and 52 were 28.94% (11/38), 36.66% (11/30) and 41.17% (7/17). Mucosal healing rates were 36.11% in CD and 43.4% in UC. During the study period, 7/52 CD patients underwent major abdominal surgery and 4/38 UC patients needed colectomy.CONCLUSION:
Vedolizumab was effective in induction and maintenance of clinical response and remission in CD and UC, with no new safety signs.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Fármacos Gastrointestinais
/
Colite Ulcerativa
/
Doença de Crohn
/
Anticorpos Monoclonais Humanizados
Tipo de estudo:
Observational_studies
Limite:
Adult
/
Female
/
Humans
/
Male
/
Middle aged
País/Região como assunto:
America do sul
/
Brasil
Idioma:
En
Ano de publicação:
2019
Tipo de documento:
Article